What question did this study set out to answer?

The study aims to investigate the effects of Syk inhibition on autoimmunity and B cell function in mice with B cell-specific TRAF3 deficiency.

April 25, 2026

Syk inhibition limits autoimmunity and abnormal B cell phenotype and function in mice with B cell-specific TRAF3 deficiency

Key Points

The study aims to investigate the effects of Syk inhibition on autoimmunity and B cell function in mice with B cell-specific TRAF3 deficiency.
B cell-specific TRAF3-deficient mice (B-Traf3−/−) were used to assess the impact of Syk inhibition with Fostamatinib.
Mice were monitored for levels of autoantibodies, inflammation, and B cell populations after treatment with the Syk inhibitor.
Analysis of pro-survival protein levels was conducted to evaluate B cell survival changes.
Syk inhibition with Fostamatinib reduced autoantibody levels and gland inflammation in B-Traf3−/− mice.
Treatment resulted in the normalization of pro-survival protein levels in TRAF3-deficient B cells.
B cell populations associated with autoimmunity were significantly reduced without inhibiting immunization responses.

Abstract

Abstract Autoimmune disorders reduce quality of life and lifespan and can increase B cell lymphoma risk. The adaptor protein TRAF3 regulates B cell survival, activation, and differentiation by restraining signaling through Toll-like receptors, tumor necrosis factor (TNF) receptor superfamily members, and the B cell antigen receptor—pathways linked to autoimmunity and lymphoma. Mice lacking TRAF3 in B cells (B-Traf3−/−) develop both autoimmunity and B cell malignancies. TRAF3 negatively regulates activation of spleen tyrosine kinase (Syk), which is involved in multiple B cell signaling pathways. B-Traf3−/− mice treated with the Food and Drug Administration (FDA)-approved Syk inhibitor Fostamatinib, exhibited reduction in autoantibodies, gland inflammation, and expansion of autoimmune-associated B cell populations. Fostamatinib also corrected enhanced pro-survival proteins and aberrant B cell survival in Traf3−/− B cells, without inhibiting humoral responses to immunization. These findings identify elevated Syk activation as a key driver of B cell dysfunction and autoimmunity in B-Traf3−/− mice, suggesting therapeutic potential for Syk inhibitors in conditions linked to decreased B cell TRAF3 levels.

Bookmark

Cite This Study

Hornick et al. (Wed,) studied this question.

synapsesocial.com/papers/69ec5b0688ba6daa22dac8f3 https://doi.org/https://doi.org/10.1093/jimmun/vkag049

Bookmark